📣 VC round data is live. Check it out!

AtriCure Valuation Multiples

Discover AtriCure's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like AdaptHealth, Wandong Medical, Sinocare, SonoScape and more.

AtriCure Overview

About AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.


Founded

2000

HQ

United States

Employees

1.4K

Financials (LTM)

Revenue: $564M
EBITDA: $70M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

AtriCure Financials

AtriCure reported last 12-month revenue of $564M and EBITDA of $70M.

In the same LTM period, AtriCure generated $425M in gross profit, $70M in EBITDA, and had net loss of ($6M).

Revenue (LTM)


AtriCure P&L

In the most recent fiscal year, AtriCure reported revenue of $535M and EBITDA of $62M.

AtriCure is unprofitable as of last fiscal year, with gross margin of 75%, EBITDA margin of 12%, and net margin of (2%).

See analyst estimates for AtriCure
LTMLast FY202320242025202620272028
Revenue$564M$535M$399M$465M$535M
Gross Profit$425M$401M$300M$348M$401M
Gross Margin75%75%75%75%75%
EBITDA$70M$62M($8M)($19M)$16M
EBITDA Margin12%12%(2%)(4%)3%
EBIT Margin(1%)(2%)(7%)(9%)(2%)
Net Profit($6M)($11M)($30M)($45M)($11M)
Net Margin(1%)(2%)(8%)(10%)(2%)

Financial data powered by Morningstar, Inc.

AtriCure Stock Performance

AtriCure has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


AtriCure's stock price is $25.86.

AtriCure share price decreased by 6.6% in the last 30 days, and by 21.1% in the last year.

AtriCure has an EPS (earnings per share) of $-0.23.

See more trading valuation data for AtriCure
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B-2.3%-6.6%-9.4%-21.1%$-0.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

AtriCure Valuation Multiples

AtriCure trades at 2.2x EV/Revenue multiple, and 17.7x EV/EBITDA.

See NTM and 2027E valuation multiples for AtriCure

EV / Revenue (LTM)


AtriCure Financial Valuation Multiples

As of June 4, 2026, AtriCure has market cap of $1B and EV of $1B.

AtriCure has a P/E ratio of (232.0x).

LTMLast FY202320242025202620272028
EV/Revenue2.2x2.3x3.1x2.7x2.3x
EV/EBITDA17.7x20.0x(152.3x)(66.6x)76.0x
EV/EBITn/m(131.3x)(46.3x)(30.9x)(130.7x)
EV/Gross Profit2.9x3.1x4.1x3.6x3.1x
P/E(232.0x)(114.4x)(43.0x)(29.3x)(114.4x)
EV/FCF29.1x29.2x(32.9x)(109.7x)29.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified AtriCure Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

AtriCure Margins & Growth Rates

AtriCure grew revenue by 13% and EBITDA by 31% in the last fiscal year.

In the most recent fiscal year, AtriCure reported gross margin of 75%, EBITDA margin of 12%, and net margin of (2%).

See estimated margins and future growth rates for AtriCure

AtriCure Margins

Last FY202420252026202720282029
Gross Margin75%75%75%76%
EBITDA Margin12%(4%)3%13%
EBIT Margin(2%)(9%)(2%)1%
Net Margin(2%)(10%)(2%)0%
FCF Margin8%(2%)8%9%

AtriCure Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth13%17%15%13%
Gross Profit Growth14%16%15%14%
EBITDA Growth31%129%(188%)397%
EBIT Growth(162%)50%(76%)(161%)
Net Profit Growth(120%)47%(74%)(120%)
FCF Growth28%(70%)(476%)28%

Data powered by FactSet, Inc. and Morningstar, Inc.

AtriCure Operational KPIs

AtriCure's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

AtriCure's Rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AtriCure's Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for AtriCure
LTMLast FY202320242025202620272028
Rule of 4025%27%---
Bessemer Rule of X44%46%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.3M---
R&D Expenses to Revenue18%19%19%21%19%
Opex to Revenue-77%82%83%77%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

AtriCure Competitors

AtriCure competitors include AdaptHealth, Wandong Medical, Sinocare, SonoScape, Tandem Diabetes Care, VCANBIO, Enovis, Nolato, Integra Lifesciences and Poly Medicure.

Most AtriCure public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
AdaptHealth1.0x1.0x5.3x5.0x
Wandong Medical4.5x4.3x(24.0x)-
Sinocare1.9x1.8x22.4x17.2x
SonoScape3.3x3.1x27.8x24.6x
Tandem Diabetes Care1.4x1.4x(31.2x)(430.9x)
VCANBIO5.1x-22.3x-
Enovis1.2x1.2x6.6x6.4x
Nolato1.4x1.4x8.5x8.5x

This data is available for Pro users. Sign up to see all AtriCure competitors and their valuation data.

Start Free Trial

Acquisitions by AtriCure

AtriCure has acquired 2 companies to date.

Last acquisition by AtriCure was on August 13th 2019. AtriCure acquired SentreHEART for $300M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by AtriCure

SentreHEART
nContact Surgical
Description
SentreHEART is a Redwood City, California-based medical device company manufacturing the LARIAT Suture Delivery Device. The system delivers a 40mm pre-tied suture loop via catheters through 4.3mm access for soft tissue closure in cardiac procedures. SentreHEART holds FDA clearance, CE Mark in Europe, and Health Canada approval for epicardial ligation applications.
nContact Surgical is a medical device company developing endoscopic treatments for cardiac arrhythmias like atrial fibrillation. Founded in 2005, it offers the Numeris Coagulation System with VisiTrax, which uses suction, perfusion, and RF energy for bi-atrial lesion creation. The system holds US indications for cardiac tissue coagulation and CE Mark approval in Europe for AF and atrial flutter treatments.
HQ CountryUnited StatesUnited States
HQ City
San Francisco, CA
Raleigh, NC
Deal Date13 Aug 20195 Oct 2015
Valuation$300M$99M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all AtriCure acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About AtriCure

When was AtriCure founded?AtriCure was founded in 2000.
Where is AtriCure headquartered?AtriCure is headquartered in United States.
How many employees does AtriCure have?As of today, AtriCure has over 1K employees.
Who is the CEO of AtriCure?AtriCure's CEO is Michael H. Carrel.
Is AtriCure publicly listed?Yes, AtriCure is a public company listed on Nasdaq.
What is the stock symbol of AtriCure?AtriCure trades under ATRC ticker.
When did AtriCure go public?AtriCure went public in 2005.
Who are competitors of AtriCure?AtriCure main competitors include AdaptHealth, Wandong Medical, Sinocare, SonoScape, Tandem Diabetes Care, VCANBIO, Enovis, Nolato, Integra Lifesciences, Poly Medicure.
What is the current market cap of AtriCure?AtriCure's current market cap is $1B.
What is the current revenue of AtriCure?AtriCure's last 12 months revenue is $564M.
What is the current revenue growth of AtriCure?AtriCure revenue growth (NTM/LTM) is 13%.
What is the current EV/Revenue multiple of AtriCure?Current revenue multiple of AtriCure is 2.2x.
What is the current EBITDA of AtriCure?AtriCure's last 12 months EBITDA is $70M.
What is AtriCure's EBITDA margin?AtriCure's last 12 months EBITDA margin is 12%.
What is the current EV/EBITDA multiple of AtriCure?Current EBITDA multiple of AtriCure is 17.7x.
What is the current FCF of AtriCure?AtriCure's last 12 months FCF is $43M.
What is AtriCure's FCF margin?AtriCure's last 12 months FCF margin is 8%.
What is the current EV/FCF multiple of AtriCure?Current FCF multiple of AtriCure is 29.1x.
How many companies AtriCure has acquired to date?As of June 2026, AtriCure has acquired 2 companies.
What was the largest acquisition by AtriCure?$300M acquisition of SentreHEART on 13th August 2019 was the largest M&A AtriCure has done to date.
What companies AtriCure acquired?AtriCure acquired SentreHEART and nContact Surgical.
In how many companies AtriCure has invested to date?AtriCure hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to AtriCure

Lists including AtriCure

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial